Finding new ways to fight antibiotic-resistant infections

Uncovering aryl polyene biology to identify new drug targets in Gram-negative bacterial pathogens

NIH-funded research Cleveland Clinic Lerner Com-Cwru · NIH-11051855

This project looks for new weaknesses in tough-to-treat bacteria to help us develop better ways to fight infections.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCleveland Clinic Lerner Com-Cwru NIH-funded
Lab location1 site (Cleveland, United States)
Project IDNIH-11051855 on NIH RePORTER

What this research studies

Antibiotic-resistant infections, especially those caused by Gram-negative bacteria, are a growing concern because current medicines are becoming less effective. These bacteria have a strong outer layer that makes them hard to treat. Our team found a special protective shield, called an aryl polyene (APE), that helps these bacteria survive our body's defenses. We want to learn exactly how these APE shields are built and placed on the bacteria. By understanding this process, we hope to discover new targets for medicines that can disarm these bacteria and make them vulnerable again.

Who could benefit from this research

Good fit: This foundational research does not directly involve patients but aims to benefit those who may suffer from severe, antibiotic-resistant Gram-negative bacterial infections in the future.

Not a fit: Patients whose infections are treatable with existing antibiotics or those with non-bacterial infections would not directly benefit from this specific approach.

Why it matters

Potential benefit: If successful, this work could lead to the development of entirely new types of medicines that target bacterial defenses rather than directly killing them, offering hope for patients with antibiotic-resistant infections.

How similar studies have performed: While the concept of targeting bacterial virulence factors is an active area of research, this specific focus on aryl polyenes as a widespread virulence factor in Gram-negative bacteria represents a novel and largely unexplored approach.

Where this research is happening

Cleveland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.